Nirupama A Nammunige
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nirupama A Nammunige has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Christine Mills
Dr Deb The Travel Doctor, Travel Medicine Alliance , Brisbane
1 shared publication Colleen L Lau
UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland , Herston
1 shared publicationDeborah J Mills
Dr Deb The Travel Doctor, Travel Medicine Alliance , Brisbane
1 shared publication- Gregor J. Devine
Mosquito Control Laboratory QIMR Berghofer Medical Research Institute Herston Queensland Australia
1 shared publication - Luis Furuya-Kanamori
Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD 4006, Australia
1 shared publication - Narayan Gyawali
Mosquito Control Laboratory QIMR Berghofer Medical Research Institute Brisbane Queensland Australia
1 shared publication
Latest Publications
- Open Access
- 21 January 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (2)
Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults
Background: Japanese encephalitis virus is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond 5 years remain limited. Methods: We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia. Participants were stratified based on the time since vaccination: 2–5 years and >5 years. Neutralizing antibody titres were measured using the plaque reduction neutralization test (PRNT50), with titres ≥10 indicating seropositivity. Results: Of the 103 participants, 47 were vaccinated 2–5 years prior and 56 were vaccinated ≥5 years prior to enrolment. All participants vaccinated within 5 years remain seropositive, whilst 52 of 56 (92.9%) vaccinated ≥5 years ago were seropositive. Four participants (7.1%) were seronegative post-vaccination, with time since vaccination ranging from 5 to 9 years. These seronegative individuals were vaccinated a median of 9.2 years ago, compared to 5.1 years for seropositive participants (P-value = 0.037). Aside from time since vaccination, no other factors (e.g. age, sex) were associated with seronegativity. Conclusions: Imojev® provides durable immunity, with seropositivity exceeding 90% up to 10 years post-vaccination. However, waning immunity in a small proportion of individuals suggests that booster doses may be beneficial for high-risk travellers vaccinated over 5 years ago.
- 21 January 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (2)
Open AccessLong-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults
Background: Japanese encephalitis virus is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond 5 years remain limited. Methods: We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia. Participants were stratified based on the time since vaccination: 2–5 years and >5 years. Neutralizing antibody titres were measured using the plaque reduction neutralization test (PRNT50), with titres ≥10 indicating seropositivity. Results: Of the 103 participants, 47 were vaccinated 2–5 years prior and 56 were vaccinated ≥5 years prior to enrolment. All participants vaccinated within 5 years remain seropositive, whilst 52 of 56 (92.9%) vaccinated ≥5 years ago were seropositive. Four participants (7.1%) were seronegative post-vaccination, with time since vaccination ranging from 5 to 9 years. These seronegative individuals were vaccinated a median of 9.2 years ago, compared to 5.1 years for seropositive participants (P-value = 0.037). Aside from time since vaccination, no other factors (e.g. age, sex) were associated with seronegativity. Conclusions: Imojev® provides durable immunity, with seropositivity exceeding 90% up to 10 years post-vaccination. However, waning immunity in a small proportion of individuals suggests that booster doses may be beneficial for high-risk travellers vaccinated over 5 years ago.